Harmony Biosciences Holdings, Inc. $HRMY Shares Purchased by Jones Financial Companies Lllp

Key Points

• Jones Financial Companies Lllp significantly increased its holdings in Harmony Biosciences by 34,496.0%, acquiring a total of 51,894 shares worth approximately $1.72 million.
• Wall Street analysts have a generally positive outlook on Harmony Biosciences, with a consensus rating of "Buy" and an average price target of $51.00.
• In its latest earnings report, Harmony Biosciences reported earnings per share of $0.68, missing the consensus estimate by $0.10 despite a 16% year-over-year increase in revenue.

Jones Financial Companies Lllp grew its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 34,496.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,894 shares of the company's stock after acquiring an additional 51,744 shares during the quarter. Jones Financial Companies Lllp owned about 0.09% of Harmony Biosciences worth $1,722,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in HRMY. Financial Management Professionals Inc. purchased a new stake in shares of Harmony Biosciences in the first quarter valued at $29,000. Brooklyn Investment Group boosted its stake in Harmony Biosciences by 1,031.9% in the 1st quarter. Brooklyn Investment Group now owns 1,064 shares of the company's stock worth $35,000 after buying an additional 970 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Harmony Biosciences in the 4th quarter worth about $41,000. Caitong International Asset Management Co. Ltd acquired a new stake in Harmony Biosciences in the 1st quarter worth about $57,000. Finally, CWM LLC boosted its stake in Harmony Biosciences by 34.8% in the 1st quarter. CWM LLC now owns 2,704 shares of the company's stock worth $90,000 after buying an additional 698 shares during the last quarter. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

Harmony Biosciences Stock Up 0.6%

Shares of NASDAQ:HRMY traded up $0.19 during mid-day trading on Wednesday, hitting $32.48. 98,011 shares of the company traded hands, compared to its average volume of 660,851. The firm has a market cap of $1.87 billion, a P/E ratio of 10.48, a PEG ratio of 0.38 and a beta of 0.84. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.80 and a current ratio of 3.84. Harmony Biosciences Holdings, Inc. has a 52-week low of $26.47 and a 52-week high of $41.61. The firm's 50 day simple moving average is $35.64 and its 200 day simple moving average is $33.53.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.10). The company had revenue of $200.49 million for the quarter, compared to analysts' expectations of $204.37 million. Harmony Biosciences had a net margin of 23.44% and a return on equity of 26.34%. The business's quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.05 earnings per share. Harmony Biosciences has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Analysts Set New Price Targets

HRMY has been the topic of a number of research analyst reports. Wall Street Zen lowered Harmony Biosciences from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. The Goldman Sachs Group initiated coverage on Harmony Biosciences in a research note on Thursday, July 10th. They issued a "neutral" rating and a $33.00 price target on the stock. Truist Financial initiated coverage on Harmony Biosciences in a research note on Monday, July 21st. They issued a "buy" rating and a $48.00 price target on the stock. Oppenheimer initiated coverage on Harmony Biosciences in a research note on Monday, June 2nd. They issued an "outperform" rating and a $61.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $55.00 price target (up from $54.00) on shares of Harmony Biosciences in a research note on Thursday, July 10th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $51.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.